Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals has launched its Phase 3 program for XEN1101, initiating the X-TOLE2 clinical trial focused on treating epilepsy. The company maintains a strong financial position with approximately $752 million in cash, ensuring funding for operations through 2026. Despite a significant drop in third-quarter revenue from $8.1 million to $0.1 million due to the end of a collaboration with Neurocrine Biosciences and no milestone payments, R&D expenses have increased to $29.4 million. A conference call to discuss these updates is scheduled for today.
Xenon Pharmaceuticals (NASDAQ:XENE) appointed Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. DiFabio joins during a critical time as the company advances multiple late-stage clinical programs aimed at commercializing epilepsy therapeutics. With extensive experience in the life sciences sector, she previously held senior legal roles at various biopharmaceutical firms, including Biogen and Repertoire Immune Medicines. Her role will focus on enhancing Xenon’s legal framework and supporting its strategic goals in neurology therapeutics.
Xenon Pharmaceuticals has initiated its Phase 3 program for XEN1101 by launching the X-TOLE2 clinical trial, targeted at treating adult patients with focal epilepsy. This follows positive Phase 2b results and successful discussions with the FDA regarding trial design. The X-TOLE2 and its parallel study, X-TOLE3, aim to evaluate XEN1101's efficacy as an adjunctive treatment, involving approximately 360 patients each. Successful outcomes could lead to a New Drug Application submission. The program reflects Xenon's commitment to addressing unmet medical needs in epilepsy treatment.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its third quarter 2022 financial results on November 8, 2022, after U.S. markets close. The company is focused on developing innovative therapies for neurological disorders, particularly epilepsy. A live conference call and audio webcast will take place at 4:30 PM ET on the same day. Investors can register for participation to receive dial-in details. Xenon is committed to addressing high unmet medical needs in the neurology sector.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 2022 results, highlighting a cash balance of $788.2 million and a cash runway extended into 2026 following a successful equity offering. The company plans to initiate the XEN1101 Phase 3 program, including the 'X-TOLE2' trial, in the second half of 2022. Recent analyses show XEN1101 rapidly reduced focal onset seizure frequency in prior trials. However, total revenue fell to $0.5 million from $2.2 million year-over-year, contributing to a net loss of $31.2 million, up from $22.1 million in Q2 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY. The company is focused on developing innovative therapeutics for neurological disorders, particularly in the area of epilepsy. A webcast of their fireside chat presentation will be available on their Investors section of the website. Xenon aims to address significant unmet medical needs through its clinical-stage product pipeline.
Xenon Pharmaceuticals has successfully closed its underwritten public offering of 9,098,362 common shares, raising approximately $287.5 million in gross proceeds. The offering included 1,229,508 shares from the underwriters’ option and 327,868 pre-funded warrants. Each common share was priced at $30.50, while pre-funded warrants were offered at $30.4999 with an exercise price of $0.0001. Major underwriters for this offering included Jefferies, J.P. Morgan, SVB Securities, and Stifel.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has priced its underwritten public offering of 7,868,854 common shares at $30.50 per share, alongside pre-funded warrants for 327,868 shares at $30.4999 each. The anticipated gross proceeds are approximately $250 million. An additional option allows underwriters to purchase up to 1,229,508 shares within 30 days. The offering is projected to close around June 27, 2022, subject to customary conditions. These transactions are part of an existing shelf registration statement with the SEC, filed on October 4, 2021.